Mother-to-child transmission of HIV

Current Opinion in Pediatrics

Volumn 10, Issue 2, 1998, Pages 143-150

  Bulterys, Marc ^a   Lepage, Philippe ^b  

^a UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^b Universitaire de Tivoli   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

BREAST FEEDING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; NEWBORN; PATIENT COUNSELING; PERINATAL PERIOD; PRIORITY JOURNAL; REVIEW; RISK MANAGEMENT; VERTICAL TRANSMISSION; VIRUS LOAD;

AGE FACTORS; CRITIQUE; DEMOGRAPHIC FACTORS; DISEASES; FAMILY AND HOUSEHOLD; FAMILY CHARACTERISTICS; FAMILY RELATIONSHIPS; HIV INFECTIONS--TRANSMISSION; INFANT; MOTHERS; PARENTS; POPULATION; POPULATION CHARACTERISTICS; VERTICAL TRANSMISSION; VIRAL DISEASES; YOUTH;

ADULT; BREAST FEEDING; CHILD; CHILD, PRESCHOOL; DEVELOPING COUNTRIES; DISEASE TRANSMISSION, VERTICAL; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; INFANT; INFANT, NEWBORN; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; RISK FACTORS; VIRAL LOAD;

EID: 0031861056     PISSN: 10408703     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008480-199804000-00005     Document Type: Review

References (82)

1. Davis SF, Byers Jr RH, Lindegren ML, Caldwell MB, Karon JM, Gwinn M: Prevalence and incidence of vertically acquired HIV infection in the United States. JAMA 1995, 247:952-955.
2. Working Group on Mother-to-Child Transmission of HIV: Rates of mother-to-child transmission of HIV-1 in Africa. America and Europe: Results from 13 perinatal studies. J Acquir Immune Defic Syndr Hum Retrovirol 1995, 8:506-510.
3. Mertens TE, Burton A: Estimates and trends of the HIV/AIDS epidemic. AIDS 1996, 10 (suppl A):S221-S228.
4. Peckham C, Gibb D: Mother-to-child transmission of the human immunodeficiency virus. N Engl J Med 1995, xx:298-302.
5. Kuhn L, Stein ZA: Mother-to-infant HIV transmission: Timing, risk factors and prevention. Paediatr Perinat Epidemiol 1995, 9:1-29.
6. John GC, Kreiss J: Mother-to-child transmission of human immunodeficiency virus type 1. Epidemiologic Reviews 1996, 18:149-157.
7. Lambert JS: Pediatric HIV infection. Curr Opin Pediatr 1996, 8:606-614.
8. Bryson YJ: Perinatal HIV-1 transmission: Recent advances and therapeutic interventions. AIDS 1996, 10 (suppl 3):533-542.
9. Siena Consensus Workshop II: Strategies for prevention of perinatal transmission of HIV infection. J Acquir Immune Defic Syndr Hum Retrovirol 1995, 8:161-175.
10. Landesman SH, Kalish SA, Burns DN, et al.: Obstetrical factors and the transmission of human immunodeficiency virus type 1 from mother to child. N Engl J Med 1996, 334:1617-1623.
11. Kalish LA, Pitt J, Lew J, et al.: Defining the time of fetal or perinatal acquisition of human immunodeficiency virus type 1 infection on the basis of age at first positive culture. J Infect Dis 1997, 175:712-715. The probabilities of a positive HIV-1 culture during the first days of life were estimated at 27% (day 0 and day 2), 45% (day 4 and day 7), 65% (day 9), 88% (day 16), and 89% (day 30).
12. Biggar RJ, Mtimavalye L, Justesen A, et al.: Does umbilical cord blood polymerase chain reaction positivity indicate in utero (pre-labor) HIV infection? AIDS 1997, 11:1375-1382.
13. Steketee RW, Abrams EJ, Thea DM, et al.: Early detection of perinatal human immunodeficiency virus (HIV) type 1 infection using HIV RNA amplification and detection. J Infect Dis 1997, 175:707-711.
14. Kuhn L, Abrams EJ, Matheson PB, et al.: Timing of maternal-infant HIV transmission: Associations between intrapartum factors and early polymerase chain reaction results. AIDS 1996, 11:429-435. In this study, 276 infants of HIV-infected women were followed prospectively and had results of early PCR tests available. Presumed intrapartum infection was found in fewer infants delivered by Cesarean section and, among infants delivered vaginally, those with more than 4 hours of membrane rupture were significantly more likely to have presumed intrapartum infection. Infants born preterm and small for gestational age had a higher risk of presumed intrapartum infection, but only those who were small for gestational age had higher risk of presumed intrauterine infection.
15. The European Collaborative Study: Vertical transmission of HIV-1: Maternal immune status and obstetric factors. AIDS 1996, 10:1675-1681. This article, which analyzes obstetric data of 1846 HIV-positive mothers with 1945 children, shows that women with low CD4 count have an increased risk of premature delivery, which would affect the timing of interventions. The fact that the risk of vertical transmission did not increase with gestational age above 35 weeks suggests that the late pregnancy period does not contribute significantly to the overall risk of transmission.
16. Kreiss J: Breastfeeding and vertical transmission of HIV-1. Acta Paediatr 1997, Suppl 421:113-117.
17. Dunn DT, Newell ML, Ades AE, et al.: Risk of human immunodeficiency virus type 1 transmission through breast feeding. Lancet 1992, 340:585-588.
18. Datta P, Embree JE, Kreiss JK, et al.: Mother-to-child transmission of human immunodeficiency virus type 1: Report from the Nairobi study. J Infect Dis 1994, 170:1134-1140.
19. Bulterys M, Chao A, Dushimimana A, Saah A: HIV-1 seroconversion after 20 months of age in a cohort of breastfed children born to HIV-1-infected women in Rwanda [letter]. AIDS 1995, 9:93-94.
20. Ekpini ER, Wiktor SZ, Satten GA, et al.: Late postnatal mother-to-child transmission of HIV-1 in Abidjan, Côte d'Ivoire. Lancet 1997, 349:1054-1059. Late postnatal transmission was diagnosed when a child had a negative PCR at 3 or 6 months of age, followed by either or both a positive HIV-1 PCR at 9 months or older, or persistently positive HIV-1 serology at 15 months or older. The study shows convincingly that breastfed children born to HIV-1 seropositive mothers are at substantial risk of late postnatal HIV transmission, thus confirming earlier reports from studies in sub-Saharan Africa. Although confidence intervals were wide, owing to the small number of cases, late postnatal transmission was more common among children with oral candidosis and among children whose mothers had a history of cracked nipples and breast abscesses.
21. American Academy of Pediatrics, Committee on Pediatric AIDS: Human milk, breastfeeding, and transmission of human immunodeficiency virus in the United States. Pediatrics 1995, 96:977-979.
22. Kuhn L, Stein Z: Infant survival, HIV infection and feeding alternatives in less-developed countries. Am J Public Health 1997, 87:926-931.
23. Nesheim SR, Shatter N, Vink P, et al.: Lack of increased risk for perinatal human immunodeficiency virus transmission to subsequent children born to infected women. Pediatr Infect Dis J 1996, 15:886-890. In this multi-center study, data were analyzed from 114 prospectively followed women who gave birth to at least two children after becoming infected with HIV to determine the risk for perinatal HIV transmission to these sibling pairs. No evidence was found for an increasing risk of transmitting HIV perinatally over time, although the observed interpregnancy interval was relatively short. Interestingly, the infection outcome of a previous child did not affect the risk of transmitting HIV-1 to subsequent children.
24. Connor EM, Sperling RS, Gelber R, et al.: Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N Engl J Med 1994, 331:1173-1180.
25. Sperling RS, Shapiro DE, Coombs RW, et al.: Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to infant. N Engl J Med 1996, 335:1621-1629. Further analysis of a randomized, placebo-controlled trial, known as the AIDS Clinical Trials Group Protocol 076, provides compelling evidence of the preventive efficacy of zidovudine. However, treatment with zidovudine produced a median reduction of only 0.24 log in plasma RNA levels. Zidovudine was effective regardless of the HIV-1 RNA level or the CD4+ count at entry.
26. Biggar RJ, Miotti PG, Taha TE, et al.: Perinatal intervention trial in Africa: Effect of a birth canal cleansing intervention to prevent HIV transmission. Lancet 1996, 347:1647-1650.
27. Fowler MG, Mofenson L: Progress in prevention of perinatal HIV-1. Acta Paediatr 1997, Suppl 421:97-103.
28. St. Louis ME, Kamenga M, Brown C, et al.: Risk for perinatal HIV-1 transmission according to maternal immunologic, virologic, and placental factors. JAMA 1993, 269:2853-2858.
29. Dickover RE, M. GE, Herman SA, et al.: Identification of levels of maternal HIV-1 RNA associated with the risk of perinatal transmission: Effect of maternal zidovudine treatment on viral load. JAMA 1996, 275:599-605.
30. Cao Y, Krogstad P, Korber BT, et al.: Maternal HIV-1 viral load and vertical transmission of infection: The Ariel Project for the prevention of HIV transmission from mother to infant. Nat Med 1997, 3:549-552. No threshold value of virus load was identified which discriminated between transmitters and non-transmitters. The results from this detailed study suggest that a high maternal viral load, while correlated with an increased risk of infection in the newborn, is insufficient to fully explain vertical transmission of HIV-1.
31. Mayaux MJ, Dussaix E, Isopet J, et al.: Maternal virus load during pregnancy and mother-to-child transmission of human immunodeficiency virus type 1: The French perinatal cohort studies. J Infect Dis 1997, 175:172-175.
32. Thea DM, Steketee RW, Pliner V, et al.: The effect of maternal viral load on the risk of perinatal transmission of HIV-1. AIDS 1997, 11:437-444. This study reports that high maternal viral load increases the likelihood of perinatal HIV-1 transmission only among women without AIDS or advanced immunosuppression. These women and their newborns may benefit the most from efforts to decrease viral load.
33. Pitt J, Brambilla D, Reichelderfer P, et al.: Maternal immunologic and virologic risk factors for infant human immunodeficiency virus type 1 infection: Findings from the women and infants transmission study. J Infect Dis 1997, 175:567-575. This report from a large US cohort looks specifically at the interaction of maternal virus burden and immune status on the risk of MCT. The authors demonstrate that maternal culture positivity during pregnancy and maternal CD4 and CD8 percentages, as well as CD8 subset percentages, each contribute to the risk of HIV transmission to the infant. In the presence of lower viral infectivity, as measured by viral culture, the integrity of the maternal immune system appeared to play a crucial role in determining the likelihood of vertical transmission.
34. Burns DN, Landesman S, Wright DJ, et al.: Influence of other maternal variables on the relationship between maternal virus load and mother-to-infant transmission of human immunodeficiency virus type 1. J Infect Dis 1997, 175:1206-1210.
35. Bulterys M, Landesman S, Burns DN, Rubinstein A, Goedert JJ: Sexual behavior and injection drug use during pregnancy and vertical transmission of HIV-1. J Acquir Immune Defic Syndr Hum Retrovirol 1997, 15:76-82. These two reports from a cohort study in New York suggest that maternal sexual behavior and injection drug use practices during the second and third trimester of pregnancy modify the risk of vertical HIV-1 transmission. The mechanism by which these behavioral factors (or other associated behaviors and exposures) increase the risk of MCT appears independent of RNA level. Elucidation of these relationships may lead to new interventions to further reduce the risk of MCT.
36. Matheson PB, Thomas PA, Abrams EJ, et al.: Heterosexual behavior during pregnancy and perinatal transmission of HIV-1. AIDS 1996, 10:1249-1256.
37. Bulterys M, Goedert JM: From biology to sexual behaviour-towards the prevention of mother-to-child transmission of HIV. AIDS 1996, 10:1287-1289.
38. Rodriguez EM, Mofenson LM, Chang B-H, et al.: Association of maternal drug use during pregnancy with maternal HIV culture positivity and perinatal HIV transmission. AIDS 1996, 10:273-282.
39. Matheson PB, Schoenbaum E, Greenberg B, Pliner V, and the New York City Perinatal HIV Transmission Collaborative Study Group: Association of maternal drug use during pregnancy with mother-to-child transmission [letter]. AIDS 1997, 11:941-942.
40. Hershow RC, Riester KA, Lew J, et al.: Increased vertical transmission of human immunodeficiency virus from hepatitis C virus-coinfected mothers. J Inf Dis 1997, 176:414-420.
41. Burns DN, Landesman S, Muenz LR, et al.: Cigarette smoking, premature rupture of membranes, and vertical transmission of HIV-1 among women with low CD4+ levels. J Acquir Immune Defic Syndr Hum Retrovirol 1994, 7:718-726.
42. Turner BJ, Hauck WW, Fanning TR, Markson LE: Cigarette smoking and maternal-child HIV transmission. J Acquir Immune Defic Syndr Hum Retrovirol 1996, 14:327-337.
43. Havens PL, Cuene BE, Hand JR, Gern JE, Sullivan BW, Chusid MJ: Effectiveness of intensive nurse case management in decreasing vertical transmission of human immunodeficiency virus infection in Wisconsin. Pediatr Infect Dis J 1997, 16:871-875.
44. Frenkel LM, Cowles MK, Shapiro DE, et al.: Analysis of the maternal components of the AIDS clinical trial group 076 zidovudine regimen in the prevention of mother-to-infant transmission of human immunodeficiency virus type 1. J Infect Dis 1997, 175:971-974.
45. De Jong MD, De Boer RJ, De Wolf F, et al.: Overshoot of HIV-1 viraemia after early discontinuation of antiretroviral treatment. AIDS 1997, 11:F79-F84. This study of five HIV-1-infected individuals who discontinued antiretroviral therapy for various reasons after 8-19 days shows transient rises in HIV-1 viremia (clearly exceeding pretreatment values) following early therapy withdrawal. This observation may have important implications for the risk of HIV-1 transmission to others and for MCT in particular.
46. Olivero OA, Anderson LM, Diwan BA, et al.: Transplacental effects of 3′-azido-2′,3′-dideoxythymidine (AZT): Tumorigenicity in mice and genotoxicity in mice and monkeys. J Natl Cancer Inst 1997, 89:1602-1608.
47. Reggy AA, Rogers MF, Simonds PJ: Using 3′-azido-2′,3′-dideoxythymidine (AZT) to prevent perinatal human immunodeficiency virus transmission and risk of transplacental carcinogenesis. J Natl Cancer Inst 1997, 89:1566-1567.
48. Spear GT, Al-Harthi L, Sha B, et al.: A potent activator of HIV-1 replication is present in the genital tract of a subset of HIV-1 infected and uninfected women. AIDS 1997, 11:1319-1326.
49. John GC, Nduati RW, Mbori-Ngacha D, et al.: Genital shedding of human immunodeficiency virus type 1 DNA during pregnancy: Association with immunosuppression, abnormal cervical or vaginal discharge, and severe vitamin A deficiency. J Infect Dis 1997, 175:57-62. In this fascinating study conducted in Nairobi, Kenya, an absolute CD4 cell count of less than 200 during pregnancy was associated with tenfold increased odds of cervical shedding of HIV-1 DNA compared with a count of 500 or greater. Detection of vaginal HIV-1 DNA was associated with abnormal vaginal discharge, lower absolute CD4 cell count, and severe vitamin A deficiency. The authors speculate that in the future, antenatal PCR testing of genital secretions could identify women who would benefit from cesarean delivery or other rational interventions.
50. Semba RD, Bulterys M, Graham NM, et al.: Maternal micronutrient deficiencies and mother-to-child transmission of human immunodeficiency virus in Rwanda. J Acquir Immune Defic Syndr Hum Retrovir 1998, in press.
51. Semba RD, Miotti PG, Chiphangwi JD, et al.: Maternal vitamin A deficiency and mother-to-child transmission of HIV-1. Lancet 1994, 343:1593-1597.
52. Greenberg BL, Semba RD, Vink PE, et al.: Vitamin A deficiency and maternal-infant transmission of HIV in two metropolitan areas in the United States. AIDS 1997, 11:325-332.
53. Burger H, Kovacs A, Weiser B, et al.: Maternal serum vitamin A levels are not associated with mother-to-child transmission of HIV-1 in the United States. J Acquir Immune Defic Syndr Hum Retrovirol 1997, 14:321-326.
54. Newell M-L, Peckham C, Dunn D, Ades A: Natural history of vertically acquired human immunodeficiency virus-1 infection. Pediatrics 1994, 94:815-819.
55. Italian Register for HIV Infection in Children: Features of children perinatally infected with HIV-1 surviving longer than 5 years. Lancet 1994, 343:191-195.
56. Grubman S, Gross E, Lerner-Weiss N, et al.: Older children and adolescents living with perinatally acquired human immunodeficiency virus. Pediatrics 1995, 95:657-663.
57. Martin N, Koup R, Kaslow R, Coffin J, Ammann A: Workshop on perinatally acquired human immunodeficiency virus type 1 infection in long-term surviving children: A collaborative study of factors contributing to slow disease progression. AIDS Res Hum Retrovir 1996, 12:1565-1570.
58. Barnhart HX, Caldwell B, Thomas P, et al.: Natural history of human immunodeficiency virus disease in perinatally infected children: An analysis from the pediatric spectrum of disease project. Pediatrics 1996, 97:710-716. Markov modeling using the CDC 1994 pediatric HIV classification on 2148 perinatally infected children showed that, on average, children progress to moderate symptoms in the second year of life and remain moderately symptomatic for more than half of their expected lives.
59. Blanche S, Newell M-L, Mayaux M-J, et al.: Morbidity and mortality in European children vertically infected by HIV-1. J Acquir Immune Defic Syndr Hum Retrovirol 1997, 14:442-450. HIV disease progression of 392 infected children enrolled in two European prospective studies is described. Twenty percent progress to a severe form of HIV disease or HIV-related death during the first year of life. After 6 years, 75% are still alive.
60. Forsyth BWC, Andiman WA, O'Connor T: Development of a prognosis-based clinical staging system for infants infected with human immunodeficiency virus type 1. J Pediatr 1996, 129:648-655. A clinical staging system to predict survival of infected infants was developed. This system is somewhat simpler than the 1994 revised CDC pediatric HIV classification system [MMWR 1994; 43:1-10]. It should prove useful for discussion about prognosis and for therapeutic decision making.
61. Pizzo PA, Wilfert CM, and the Pediatric AIDS Sienna Workshop II: Markers and determinants of disease progression in children with HIV infection. J Acquir Immune Defic Syndr Hum Retrovirol 1995, 8:30-44.
62. Mayaux M-J, Burgard M, Teglas J-P, et al.: Neonatal characteristics in rapidly progressive perinatally acquired HIV-1 disease. JAMA 1996, 275:606-610. This study from the French Pediatric HIV Study Group shows that the risk of category C events (opportunistic infections, recurrent bacterial infections, cancers, encephalopathy and wasting syndrome) is increased when an infected newborn has liver and/or spleen enlargement and/or adenopathies, or a low proportion of CD4 cells at birth. HIV-1 culture and/or PCR positivity is also associated with an increased risk of rapid disease progression.
63. Kourtis AP, Ibegbu C, Nahmias AJ, Lee FK, Clark WS, Sawyer MK, Nesheim S: Early progression of disease in HIV-infected infants with thymus dysfunction. N Engl J Med 1996, 335:1431-1436. In this study of 59 infected infants, 17 developed a pattern of lymphocyte depletion that resembles congenital thymic deficiency. HIV disease progressed rapidly in these infants.
64. McIntosh K, Shevitz A, Zaknun D, et al.: Age- and time-related changes in extracellular viral load in children vertically infected by human immunodeficiency virus. Pediatr Infect Dis J 1996, 15:1087-1091.
65. De Rossi A, Masiero S, Giaquinto C, et al.: Dynamics of viral replication in infants with vertically acquired human immunodeficiency virus type 1 infection. J Clin Invest 1996, 97:323-330.
66. Shearer WT, Quinn TC, LaRussa P, et al.: Viral load and disease progression in infants infected with human immunodeficiency virus type 1. N Engl J Med 1997, 336:1337-1342. The results from this important study show that, in perinatally infected infants, HIV RNA levels are high and fall very gradually in the first years of life.
67. Mofenson LM, Korelitz J, Meyer III WA, et al.: The relationship between serum human immunodeficiency virus type 1 (HIV-1) RNA level, CD4 lymphocyte percent, and long-term mortality risk in HIV-1-infected children. J Infect Dis 1997, 175:1029-1038. As previously demonstrated in adults [Science 1996; 272:1167-1170], high viral load resulted in more rapid disease progression.
68. + cell count, acquired immunodeficiency syndrome, and viral load on disease progression in infants with perinatally acquired human immunodeficiency virus type 1 infection. J Pediatr 1997, 130:890-897. In a multivariate analysis, high maternal viral load and maternal AIDS were independently associated with shorter time to CDC category C disease or death in infected infants.
69. Blanche S, Mayaux M-J, Rouzioux C, et al.: Relation of the course of HIV infection in children to the severity of the disease in their mothers at delivery. N Engl J Med 1994, 330:308-312.
70. Moye JJ, Rich KC, Kalish LA, et al.: Natural history of somatic growth in infants born to women infected by human immunodeficiency virus. J Pediatr 1996, 128:58-69. Few data are available on the anthropometric characteristics of infected children. This prospective study from the United States emphasizes the negative impact of perinatally acquired HIV infection on growth (weight for age, height for age, head circumference for age and body mass index).
71. Lepage P, Msellati P, Hitimana DG, et al.: Growth of HIV-1-infected and uninfected children. A prospective cohort study in Kigali, Rwanda, 1988-1993. Pediatr Infect Dis J 1996, 15:479-485. In this African study, anthropometric characteristics of uninfected children born to infected mothers were similar to those of children born to uninfected mothers.
72. Zaknun D, Orav J, Kornegay J, et al.: Correlation of ribonucleic acid polymerase chain reaction, acid dissociated p24 antigen, and neopterin with progression of disease: A retrospective, longitudinal study of vertically acquired human immunodeficiency virus type 1 infection in children. J Pediatr 1997, 130:898-905. Measurements of viral load were useful prognostic indicators for poor growth in this study.
73. Pollack H, Glasberg H, Lee E, et al.: Impaired early growth of infants perinatally infected with human immunodeficiency virus: Correlation with viral load. J Pediatr 1997, 130:896-905. In this retrospective study, the negative effect of HIV on linear growth was correlated with the level of postnatal HIV viremia.
74. Blanche S, Mayaux M-J, Veber F, et al.: Separation between HIV-positive women and their children: The French Prospective Study, 1986 through 1993. Am J Public Health 1996, 86:376-381. There was an added risk of separation between infected women and their children when the mother's HIV exposure mode was intravenous drug use. After separation, 57% of the children were placed through child welfare services and 43% were cared for by relatives.
75. Thorne C, Newell ML, Dunn D, Peckham C: Hospitalization of children born to human immunodeficiency virus-infected women in Europe. Pediatr Infect Dis J 1997, 16:1151-1152. Interesting description of the pattern of inpatient hospital service use in the first 5 years of life in 10 centers of the European Collaborative Study. It was estimated that 48% of infected and 17% of uninfected children had been hospitalized by 12 months of age.
76. Spira R-M, Msellati P: Natural history of pediatric HIV infection in developing countries. Care of HIV Infected Children in Developing Countries: A Workshop for Clinical Research. Paris, France: September 26-27, 1997.
77. Lucas SB, Peacock CS, Hounnou A, et al.: Disease in children with HIV in Abidjan, Côte d'Ivoire. Br Med J 1996, 312:335-338. Necropsy study of 78 HIV-infected and 77 uninfected children. Respiratory tract infections were more common in infected children. Pneumocystis carinii pneumonia was found in 31% of infected subjects less than 15 months of age, but in no uninfected children. Among older children, measles was more common in infected children.
78. Mukadi YD, Wiktor SZ, Coulibaly I-M, et al.: Impact of HIV infection on the development, clinical presentation, and outcome of tuberculosis among children in Abidjan, Côte d'Ivoire. AIDS 1997, 11:1151-1158. A total of 161 children with tuberculosis were enrolled to assess the impact of HIV infection on the development, clinical presentation and outcome of tuberculosis in children. Children with tuberculosis were more likely than control subjects to be HIV-seropositive. The distribution of radiologic abnormalities was similar in seropositive and seronegative children. The mortality rate was significantly higher in seropositive children.
79. Coutsoudis A, Bobat RA, Coovadia HM, Kuhn L, Tsai WY, Stein ZA: The effect of vitamin A supplementation on the morbidity of children born to HIV-infected women. Am J Public Health 1995, 85:1076-1081.
80. Zierler S, Krieger N: Reframing women's risk: Social inequalities and HIV infection. Annu Rev Public Health 1997, 18:401-436.
81. Centers for Disease Control and Prevention: Update: Perinatally acquired HIV/AIDS-United States, 1997. MMWR 1997, 46:1087-1095.
82. Centers for Disease Control and Prevention: Administration of zidovudine during late pregnancy and delivery to prevent perinatal HIV transmission-Thailand, 1996-1998. MMWR 1998; 47:151-154.